Últimas noticias sobre Terns Pharma (NASDAQ:TERN) Bolsa

Terns Pharma

Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharmaceuticals Inc

Tern PLC

TERNIUM ARGENTINA S A by TERNIUM ARGENTINA S A

Terna Energy SA

TERNA ENERGY SA UNSP/ADR by Terna Energy SA

TRASMISSIONE ELECTR ORD by Terna Rete Elettrica Nazionale SPA

Terna SpA

TERNA RETE ELETTRICA ADR by Terna Rete Elettrica Nazionale SPA

Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares, USD1.00 par value)

Ternium SA

Ternoa

<p><a href="https://www.benzinga.com/digital-assets/livestream" title="https://www.benzinga.com/digital-assets/livestream">https://www.benzinga.com/digital-assets/livestream</a></p>


News

Events

Exclusives

$BTC

Robert Mitchnick, Head of Digital Assets, BlackRock Says We're At Such An Early Stage In The Crypto Education Journey For So Many Different Investor Types

WIIM

NRDY

Nerdy Inc. shares are trading higher following a purchase of shares by CEO Charles K. Cohn.

Robert Mitchnick, Head of Digital Assets, BlackRock Says Inflows Into BlackRock's iShares Bitcoin Trust Options Was Over $1B As Of This Afternoon

Robert Mitchnick, Head of Digital Assets, BlackRock Says A Lot Of The Trends We've Seen This Year Are Probably Well-Positioned To Continue

SYRS

Syros Pharmaceuticals shares are trading higher after falling on Monday after the company announced it gave notice to QIAGEN Manchester of its election to terminate the Master Collaboration Agreement.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

Robert Mitchnick, Head of Digital Assets, BlackRock Says If You Look At The Trends In Bitcoin's Dominance, It's Been Pretty Staggering...It's In A Different Category Today Than The Rest Of Crypto

<p>Financial giants have made a conspicuous bearish move on Alnylam Pharmaceuticals. Our analysis of options history for Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) revealed 11 unusual trades.</p>
<p>Delving into the details, we found 27% of traders were bullish, while 45% showed bearish tendencies. Out of all the trades we spotted, 9 were puts, with a value of $515,770, and 2 were calls, valued at $88,650.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $210.0 to $290.0 for Alnylam Pharmaceuticals during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Alnylam Pharmaceuticals's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Alnylam Pharmaceuticals's significant trades, within a strike price range of $210.0 to $290.0, over the past month.</p>
<h3>Alnylam Pharmaceuticals Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732049153_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$15.5</td>
<td>$15.5</td>
<td>$15.5</td>
<td>$240.00</td>
<td>$130.2K</td>
<td align="right">517</td>
<td align="right">100</td>
</tr>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$3.5</td>
<td>$3.0</td>
<td>$3.5</td>
<td>$210.00</td>
<td>$62.6K</td>
<td align="right">170</td>
<td align="right">457</td>
</tr>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$58.5</td>
<td>$55.9</td>
<td>$57.0</td>
<td>$290.00</td>
<td>$57.0K</td>
<td align="right">241</td>
<td align="right">40</td>
</tr>
<tr>
<td>ALNY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$54.0</td>
<td>$50.5</td>
<td>$54.0</td>
<td>$250.00</td>
<td>$54.0K</td>
<td align="right">0</td>
<td align="right">10</td>
</tr>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$50.1</td>
<td>$46.6</td>
<td>$48.1</td>
<td>$280.00</td>
<td>$52.9K</td>
<td align="right">395</td>
<td align="right">11</td>
</tr>
</tbody>
</table>
</p>
<h3>About Alnylam Pharmaceuticals</h3>
<p>Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.</p>
<p>In light of the recent options history for Alnylam Pharmaceuticals, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Alnylam Pharmaceuticals's Current Market Status</h3>
<ul>
<li>With a volume of 446,657, the price of ALNY is up 0.74% at $233.99. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 86 days.</li>
</ul>
<h3>What Analysts Are Saying About Alnylam Pharmaceuticals</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $350.2.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Buy rating for Alnylam Pharmaceuticals, targeting a price of $384.<br />
&#x2A; An analyst from Piper Sandler downgraded its action to Overweight with a price target of $296.<br />
&#x2A; An analyst from HC Wainwright &amp; Co. downgraded its action to Buy with a price target of $400.<br />
&#x2A; An analyst from RBC Capital has revised its rating downward to Outperform, adjusting the price target to $300.<br />
&#x2A; An analyst from TD Cowen persists with their Buy rating on Alnylam Pharmaceuticals, maintaining a target price of $371. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Alnylam Pharmaceuticals, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

ALNY

This Is What Whales Are Betting On Alnylam Pharmaceuticals

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Arista Networks</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ANET, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 30 uncommon options trades for Arista Networks.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 33% bullish and 30%, bearish.</p>
<p>Out of all of the special options we uncovered, 9 are puts, for a total amount of $342,871, and 21 are calls, for a total amount of $1,005,778.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $260.0 to $460.0 for Arista Networks over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Arista Networks's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Arista Networks's whale trades within a strike price range from $260.0 to $460.0 in the last 30 days. </p>
<h3>Arista Networks Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732049148_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$49.1</td>
<td>$47.5</td>
<td>$48.4</td>
<td>$380.00</td>
<td>$91.9K</td>
<td align="right">110</td>
<td align="right">21</td>
</tr>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$15.3</td>
<td>$14.6</td>
<td>$14.7</td>
<td>$430.00</td>
<td>$80.8K</td>
<td align="right">171</td>
<td align="right">114</td>
</tr>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$18.0</td>
<td>$17.4</td>
<td>$17.43</td>
<td>$420.00</td>
<td>$80.3K</td>
<td align="right">309</td>
<td align="right">52</td>
</tr>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$2.7</td>
<td>$2.1</td>
<td>$2.45</td>
<td>$460.00</td>
<td>$73.5K</td>
<td align="right">502</td>
<td align="right">311</td>
</tr>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$13.3</td>
<td>$12.6</td>
<td>$12.6</td>
<td>$430.00</td>
<td>$69.3K</td>
<td align="right">171</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About Arista Networks</h3>
<p>Arista Networks is a networking equipment provider that primarily sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system, or EOS, that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three quarters of its sales from North America.</p>
<p>In light of the recent options history for Arista Networks, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Arista Networks's Current Market Status</h3>
<ul>
<li>With a volume of 2,357,777, the price of ANET is up 1.84% at $377.3. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 83 days.</li>
</ul>
<h3>Professional Analyst Ratings for Arista Networks</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $424.2.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Arista Networks with a target price of $495.<br />
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on Arista Networks, maintaining a target price of $460.<br />
&#x2A; An analyst from UBS persists with their Neutral rating on Arista Networks, maintaining a target price of $425.<br />
&#x2A; An analyst from Piper Sandler has revised its rating downward to Neutral, adjusting the price target to $421.<br />
&#x2A; Maintaining their stance, an analyst from Rosenblatt continues to hold a Sell rating for Arista Networks, targeting a price of $320. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Arista Networks, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


ANET

A Closer Look at Arista Networks's Options Market Dynamics

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Novo Nordisk</strong>.</p>
<p>Looking at options history for Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) we detected 45 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 57% of the investors opened trades with bullish expectations and 40% with bearish.</p>
<p>From the overall spotted trades, 11 are puts, for a total amount of $549,674 and 34, calls, for a total amount of $2,045,493.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $70.0 to $130.0 for Novo Nordisk during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Novo Nordisk's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Novo Nordisk's whale trades within a strike price range from $70.0 to $130.0 in the last 30 days. </p>
<h3>Novo Nordisk Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732049142_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.34</td>
<td>$2.22</td>
<td>$2.23</td>
<td>$115.00</td>
<td>$289.9K</td>
<td>11.2K</td>
<td>3.4K</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$5.7</td>
<td>$5.6</td>
<td>$5.66</td>
<td>$105.00</td>
<td>$190.8K</td>
<td>2.1K</td>
<td>557</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$5.7</td>
<td>$5.6</td>
<td>$5.7</td>
<td>$105.00</td>
<td>$152.7K</td>
<td>2.1K</td>
<td>994</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$19.05</td>
<td>$18.8</td>
<td>$18.8</td>
<td>$120.00</td>
<td>$112.8K</td>
<td>1.9K</td>
<td>71</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.0</td>
<td>$4.95</td>
<td>$4.95</td>
<td>$97.50</td>
<td>$99.5K</td>
<td>2.4K</td>
<td>224</td>
</tr>
</tbody>
</table>
</p>
<h3>About Novo Nordisk</h3>
<p>With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.</p>
<p>Having examined the options trading patterns of Novo Nordisk, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Novo Nordisk's Current Market Status</h3>
<ul>
<li>With a trading volume of 4,369,108, the price of NVO is up by 2.64%, reaching $102.44.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 71 days from now.</li>
</ul>
<h3>Expert Opinions on Novo Nordisk</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $160.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $160. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Novo Nordisk, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Novo Nordisk Unusual Options Activity For November 19

SOAR

Volato Group shares are trading higher. The stock may be rising on continued strength after the company recently reported a year-over-year increase in Q3 financial results.

Anthony Dixon, Digital Assets Product Manager, FTSE Russell / LSEG Says Looking Forward, I Think We Can See Some More Elaborate Products In The Crypto Space

Zach Pandl, Managing Director, Research, Grayscale Investments Says Macro Case: The High Inflation, Legacy Of Government Debt, Fragmenting International Monetary System Are What Drives People To Bitcoin

IBRX

ImmunityBio shares are trading higher after the company announced the completion of ANKTIVA's post-approval enrollment of the 100th patient in the BCG unresponsive NMIBC CIS trial. Additionally, D. Boral Capital maintained a Buy rating on the stock.

Interview

Franklin Templeton Research Analyst David Alderman Says Imagines Stablecoins Will Be More Active, Institutional Investors Will Have Easier Access To The Different Types Of Crypto Products They Want

FUTU

Futu Holdings shares are trading lower after the company reported worse-than-expected Q3 adjusted EPS results. Also, Citigroup downgraded the stock from Buy to Neutral.

DTCC Digital Assets Executive Director Jennifer O'Rourke Says Just Because Bill Is Passed Into Law Does Not Mean It Is Ready To Go Compliance Wise, There Are Other Procedural Things That Need To Happen Afterwards Including Rule And Commentary Process, Harmonization Between Agencies, Need To Have Deeper Education And Adoption Process By The Market Participants

<p>On Monday, <strong>Silence Therapeutics plc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42046710/silence-therapeutics-presents-late-breaking-phase-2-zerlasiran-data-at-2024-american-heart-associa" rel="noreferrer noopener">levels (≥125 nmol/L)</a>.</p>
<p>These data were presented at the American Heart Association (AHA) Scientific Sessions.</p>
<p>Results showed that zerlasiran (300 mg every 16 weeks, 300 mg every 24 weeks or 450 mg every 24 weeks) produced greater than 80% mean time-averaged placebo-adjusted reductions from baseline in Lp(a) concentrations over 36 weeks.</p>
<p>This is the first study to report time-averaged Lp(a) analyses, which more accurately evaluate the effects of treatment over time, including intervals between doses.</p>
<p>Maximum Lp(a) reductions exceeded 90%. At the final visit, 60 weeks following initial drug administration, reductions in Lp(a) persisted, and no safety concerns emerged with infrequent dosing.</p>
<p><strong>William Blair</strong> notes that while Silence's data shows the drug effectively lowers Lp(a) levels, the Q24W dosing schedule may not be competitive. This is due to a decline in Lp(a) reduction between doses.</p>
<p>This dosing schedule could be an option for maintenance after stable Lp(a) reductions are reached. However, the analyst expects more frequent dosing, possibly every three months, to be needed. This may reduce zerlasiran's competitive edge compared to <strong>Amgen Inc.'s </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) olpasiran.</p>
<p>The analyst writes, "Silence continues to execute on both the zerlasiran and divesiran lead clinical programs. While data for zerlasiran presented at AHA show that zerlasiran is an efficacious Lp(a) lowering agent over 48 weeks with Q24W dosing, we are incrementally negative on zerlasiran's competitive profile given the waning of Lp(a) lowering between the infrequent doses, which has not been demonstrated with olpasiran at a once-quarterly dosing frequency."</p>
<p><strong>Price Action: </strong>SLN stock is down 33.80% at $7.20 at the last check on Tuesday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/24/11/42073438/aclaris-stock-soars-as-analysts-see-fresh-momentum-after-strategic-review-and-encouraging-promising-pipeline-developments"><strong>Aclaris </strong></a><strong><a href="https://www.benzinga.com/24/11/42073438/aclaris-stock-soars-as-analysts-see-fresh-momentum-after-strategic-review-and-encouraging-promising-pipeline-developments">Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments</a></strong></li>
</ul>


Analyst Color

Biotech

Health Care

Price Target

Analyst Ratings

Movers

Trading Ideas

General

AMGN

Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst

<p>Analysts expect <strong>Target Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) to report third-quarter revenue of $25.9 billion when the company reports third-quarter financial results on Wednesday, Nov. 20 <a href="https://www.benzinga.com/earnings">before the market opens.</a></p>
<p> That&#8217;s up from $25.4 billion in last year's third quarter, according to data <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111924&amp;t=be2bearmibe3na1">from Benzinga Pro.</a></p>
<p>The Minneapolis-based company has beaten analyst estimates for revenue in six of the last eight quarters and seven of the last 10 quarters overall.</p>
<p>Analysts expect Target to report third-quarter earnings per share of $2.30 — up from $2.10 in last year's third quarter. The company has beaten analyst estimates in six of the last seven quarters and six of the last 10 quarters overall.</p>
<p><a href="https://www.benzinga.com/news/earnings/24/08/40482203/target-q2-earnings-revenue-and-profit-beat-digital-sales-boost-annual-profit-outlook-hiked">Guidance from Target </a>calls for third-quarter comparable sales to be up 0% to 2% year-over-year. The company also guided for third-quarter earnings per share to be in the range of $2.10 to $2.40.</p>
<p>Target raised its full-year guidance after second-quarter results with earnings per share of $9.00 to $9.70 now expected, up from a prior range of $8.60 to $9.60.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/news/earnings/24/11/42068978/how-to-earn-500-a-month-from-target-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Target Stock Ahead Of Q3 Earnings</a></strong></p>
<h3 class="wp-block-heading"><strong>Key Items to Watch</strong></h3>
<p>Target visitor traffic was up 1% year-over-year, per data from Placer.ai. It outpaced retail rival<strong> Walmart Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>), which had 0.9% visitor growth year-over-year.</p>
<p>The Placer.ai <a href="https://www.placer.ai/blog/superstores-and-wholesale-clubs-ahead-of-the-holidays">report</a> also sheds some light on upcoming trends to watch for Target and how the company's guidance could factor into the holiday season. Target saw the biggest weekly holiday visits boost of the tracked retail chains, with foot traffic up 87.3% the week before Christmas compared to the company's weekly average. </p>
<p>Walmart, by comparison, saw a 39.6% increase in its weekly average visitors for the week before Christmas last year.</p>
<p>"Digging deeper into historical data suggests that it is Target that is primed to experience the busiest holiday season of the analyzed chains," Placer.ai said.</p>
<p>Target also saw the biggest spike of the tracked retailers for the weekly visitor growth for the week of Turkey Wednesday and Black Friday, with visits up 18.9% compared to the company's weekly average.</p>
<p>"With recent visits to Target on par with — or slightly above — last year's levels, the retail giant is likely poised to win the holidays once again."</p>
<p>Along with guidance and commentary on the holiday shopping season, another area to watch in Target's report will be same-day delivery services. The company reported a double-digit increase in this segment in the second quarter.</p>
<p>Sales by segment could also be an area to watch with Target saying apparel and discretionary sales were strong in the second quarter.</p>
<p>Target's quarterly results come one day after Walmart <a href="https://www.benzinga.com/24/11/42060801/walmart-tops-q3-estimates-ecommerce-growth-shines-with-27-lifts-full-year-forecast">reported third-quarter results</a>. Walmart reported revenue and earnings per share that came in ahead of Street consensus estimates. The retailers also raised its guidance.</p>
<p>The strong quarterly report from Walmart could be a positive for Target heading into the earnings report as it could signal the strength of the American consumer. The key will be making sure that Walmart didn't end up taking market share away from Target as a result.</p>
<p><strong>Price Action: </strong>Target stock is down 1% to $155.37 on Tuesday versus a 52-week trading range of $128.37 to $181.86. Target stock is up 8.6% year-to-date in 2024.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/general/entertainment/24/10/41338328/taylor-swift-teams-up-with-target-for-exclusive-black-friday-merch-will-swifties-boost-q4-s">Taylor Swift Teams Up With Target For Exclusive Black Friday Merch: Will Swifties Boost Q4 Sales, Prove Donald Trump Wrong?</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Previews

Target Q3 Earnings Preview: Analysts Expect Revenue, EPS Growth As Attention Turns To Holiday Quarter

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>CVS Health</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CVS, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 13 uncommon options trades for CVS Health.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 38% bullish and 61%, bearish.</p>
<p>Out of all of the special options we uncovered, 7 are puts, for a total amount of $668,128, and 6 are calls, for a total amount of $310,421.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $50.0 to $80.0 for CVS Health over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for CVS Health options trades today is 1767.3 with a total volume of 21,448.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for CVS Health's big money trades within a strike price range of $50.0 to $80.0 over the last 30 days.</p>
<h3>CVS Health Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732048235_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$1.27</td>
<td>$1.1</td>
<td>$1.1</td>
<td>$56.00</td>
<td>$219.5K</td>
<td>594</td>
<td>2.0K</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/22/24</td>
<td>$1.25</td>
<td>$1.1</td>
<td>$1.1</td>
<td>$56.00</td>
<td>$141.0K</td>
<td>594</td>
<td>3.3K</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.0</td>
<td>$0.98</td>
<td>$0.99</td>
<td>$54.00</td>
<td>$106.4K</td>
<td>57</td>
<td>1.1K</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$0.95</td>
<td>$0.94</td>
<td>$0.95</td>
<td>$56.00</td>
<td>$86.6K</td>
<td>527</td>
<td>919</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$1.35</td>
<td>$1.32</td>
<td>$1.32</td>
<td>$60.00</td>
<td>$72.8K</td>
<td>10.4K</td>
<td>960</td>
</tr>
</tbody>
</table>
</p>
<h3>About CVS Health</h3>
<p>CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.</p>
<h3>CVS Health's Current Market Status</h3>
<ul>
<li>With a trading volume of 6,498,681, the price of CVS is down by -0.72%, reaching $55.65.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 78 days from now.</li>
</ul>
<h3>Expert Opinions on CVS Health</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $65.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Mizuho has decided to maintain their Outperform rating on CVS Health, which currently sits at a price target of $66.<br />
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Equal-Weight rating for CVS Health, targeting a price of $60.<br />
&#x2A; An analyst from UBS persists with their Neutral rating on CVS Health, maintaining a target price of $62.<br />
&#x2A; An analyst from Barclays persists with their Overweight rating on CVS Health, maintaining a target price of $71.<br />
&#x2A; In a positive move, an analyst from Wells Fargo has upgraded their rating to Overweight and adjusted the price target to $66. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for CVS Health, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


CVS Health Options Trading: A Deep Dive into Market Sentiment

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Roblox</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with RBLX, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 15 uncommon options trades for Roblox.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 60% bullish and 33%, bearish.</p>
<p>Out of all of the special options we uncovered, 5 are puts, for a total amount of $259,440, and 10 are calls, for a total amount of $562,301.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $40.0 to $80.0 for Roblox during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In today's trading context, the average open interest for options of Roblox stands at 3636.38, with a total volume reaching 16,256.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Roblox, situated within the strike price corridor from $40.0 to $80.0, throughout the last 30 days.</p>
<h3>Roblox Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732048230_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>RBLX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$4.65</td>
<td>$4.6</td>
<td>$4.6</td>
<td>$48.00</td>
<td>$111.3K</td>
<td>12.4K</td>
<td>2.6K</td>
</tr>
<tr>
<td>RBLX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/29/24</td>
<td>$4.25</td>
<td>$4.25</td>
<td>$4.25</td>
<td>$48.00</td>
<td>$79.0K</td>
<td>12.4K</td>
<td>1.9K</td>
</tr>
<tr>
<td>RBLX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$4.65</td>
<td>$4.6</td>
<td>$4.6</td>
<td>$48.00</td>
<td>$73.1K</td>
<td>12.4K</td>
<td>2.2K</td>
</tr>
<tr>
<td>RBLX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$4.15</td>
<td>$4.15</td>
<td>$4.15</td>
<td>$48.00</td>
<td>$63.5K</td>
<td>12.4K</td>
<td>1.0K</td>
</tr>
<tr>
<td>RBLX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$3.7</td>
<td>$3.65</td>
<td>$3.65</td>
<td>$50.00</td>
<td>$62.7K</td>
<td>11</td>
<td>172</td>
</tr>
</tbody>
</table>
</p>
<h3>About Roblox</h3>
<p>Roblox operates an online video game platform with 80 million daily active users that lets young gamers create, develop, and monetize games (or "experiences") for other players. The firm offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning $3.5 billion in bookings in 2023 through in-game purchases and advertising while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers than creating new games or franchises.</p>
<p>In light of the recent options history for Roblox, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Roblox</h3>
<ul>
<li>With a volume of 4,103,597, the price of RBLX is up 2.78% at $52.45. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 78 days.</li>
</ul>
<h3>Expert Opinions on Roblox</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $56.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Goldman Sachs persists with their Neutral rating on Roblox, maintaining a target price of $55.<br />
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on Roblox, maintaining a target price of $58.<br />
&#x2A; Consistent in their evaluation, an analyst from Benchmark keeps a Buy rating on Roblox with a target price of $60.<br />
&#x2A; An analyst from Macquarie persists with their Outperform rating on Roblox, maintaining a target price of $58.<br />
&#x2A; In a cautious move, an analyst from Wedbush downgraded its rating to Outperform, setting a price target of $49. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Roblox, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


RBLX

Roblox Unusual Options Activity For November 19

Let's talk about insider trading. Not the illegal kind, but the perfectly normal – and fully legal – trading by top-level corporate officers. These...

Insiders Snap Up These 2 'Strong Buy' Stocks

Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Wingstop upgraded, Estee Lauder downgraded: Wall Street's top analyst calls

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on TERN stock, giving a Buy rating yesterday. Graig Suvannavejh has...

Optimistic Outlook for Terns Pharmaceuticals: Potential of TERN-701 Amidst Market Opportunities

"Our progress in the third quarter was highlighted by the compelling topline results from our Phase 1 study of TERN-601, which demonstrated class-l...

Terns Pharmaceuticals reports Q3 EPS (28c), consensus (32c)

Analyst Silvan Tuerkcan of JMP Securities maintained a Buy rating on Terns Pharmaceuticals (TERN – Research Report), retaining the price target of ...

Terns Pharmaceuticals: Promising Oncology Developments and Strategic Pipeline Diversification Justify Buy Rating

Etzer Darout, an analyst from BMO Capital, has initiated a new Buy rating on Terns Pharmaceuticals (TERN). Etzer Darout's rating is based on a comb...

Terns Pharmaceuticals: Promising Clinical Developments and Strong Financial Position Justify Buy Rating

TD Cowen analyst Ritu Baral has maintained their bullish stance on TERN stock, giving a Buy rating yesterday. Ritu Baral has given his Buy rating d...

Promising Phase 1/2 Study and Strong Financials Drive Buy Rating for Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. ( ($TERN) ) has released its Q3 earnings. Here is a breakdown of the information Terns Pharmaceuticals, Inc. presented ...

Terns Pharmaceuticals Reports Q3 Progress and Financials

The latest update is out from Terns Pharmaceuticals ( ($TERN) ). Terns Pharmaceuticals has announced the appointment of Heather Turner, a seasoned ...

Terns Pharmaceuticals Appoints Heather Turner to Board

ALGS

BRZE

ENLC

GPCR

MDGL

NVDA

ORIC

SMCI

TERN

VKTX

VNDA

WING

Press Releases

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

Earnings

Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates

Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity

Terns Announces Proposed Public Offering

IPOs

Terns Announces Pricing of Upsized $150.15 Million Public Offering

Financing

Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Comments

Terns Pharma

Noticias

Últimas noticias sobre Terns Pharma (NASDAQ:TERN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL